Cargando…
A new paradigm for classifying and treating HER2‐positive breast cancer
BACKGROUND: Because of the phenomenal success of treatment with monoclonal antibodies and antibody‐drug conjugates targeting human epidermal growth factor receptor 2 (HER2), most patients with early‐stage HER2‐positive breast cancer (HER2+ BC) and some with limited metastatic diseases have been cure...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432420/ https://www.ncbi.nlm.nih.gov/pubmed/37254964 http://dx.doi.org/10.1002/cnr2.1841 |
_version_ | 1785091406267678720 |
---|---|
author | He, Xuexin Yeung, Sai‐Ching J. Esteva, Francisco J. |
author_facet | He, Xuexin Yeung, Sai‐Ching J. Esteva, Francisco J. |
author_sort | He, Xuexin |
collection | PubMed |
description | BACKGROUND: Because of the phenomenal success of treatment with monoclonal antibodies and antibody‐drug conjugates targeting human epidermal growth factor receptor 2 (HER2), most patients with early‐stage HER2‐positive breast cancer (HER2+ BC) and some with limited metastatic diseases have been cured, and those who have not been cured have achieved significant improvements in overall survival, which has weakened the role of the TNM staging system in the prognosis of HER2+ BC today. Given that the disease is now highly curable, treatment conception, classification, and modalities should differ from those of cancer types with a poor prognosis. It is warranted to build a new paradigm for classifying and treating HER2+ BC. RECENT FINDINGS: In our personal view, we suggest that the classification system should be based not only on traditional anatomy and cancer biology but also on available treatment regimens, their exceptional outcomes, and their toxicities. In this regard, we developed a new concise classification of HER2+ BC based on the TNM staging system, a review of the literature, research results, and our clinical experience, dividing the patients into four distinct groups: curable (lymph‐node negative and small (≤3 cm) early breast cancer), do our best to cure (locally advanced or tumors >3 cm early breast cancer), hope for cure (local‐regional recurrent, limited metastases, and exceptional responders), and incurable (metastatic breast cancer with poor performance status or non‐exceptional responders). CONCLUSION: It will assist clinicians in developing an optimal treatment regimen at the outset, curing more HER2+ BC patients and improving their quality of life. |
format | Online Article Text |
id | pubmed-10432420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104324202023-08-18 A new paradigm for classifying and treating HER2‐positive breast cancer He, Xuexin Yeung, Sai‐Ching J. Esteva, Francisco J. Cancer Rep (Hoboken) Reviews BACKGROUND: Because of the phenomenal success of treatment with monoclonal antibodies and antibody‐drug conjugates targeting human epidermal growth factor receptor 2 (HER2), most patients with early‐stage HER2‐positive breast cancer (HER2+ BC) and some with limited metastatic diseases have been cured, and those who have not been cured have achieved significant improvements in overall survival, which has weakened the role of the TNM staging system in the prognosis of HER2+ BC today. Given that the disease is now highly curable, treatment conception, classification, and modalities should differ from those of cancer types with a poor prognosis. It is warranted to build a new paradigm for classifying and treating HER2+ BC. RECENT FINDINGS: In our personal view, we suggest that the classification system should be based not only on traditional anatomy and cancer biology but also on available treatment regimens, their exceptional outcomes, and their toxicities. In this regard, we developed a new concise classification of HER2+ BC based on the TNM staging system, a review of the literature, research results, and our clinical experience, dividing the patients into four distinct groups: curable (lymph‐node negative and small (≤3 cm) early breast cancer), do our best to cure (locally advanced or tumors >3 cm early breast cancer), hope for cure (local‐regional recurrent, limited metastases, and exceptional responders), and incurable (metastatic breast cancer with poor performance status or non‐exceptional responders). CONCLUSION: It will assist clinicians in developing an optimal treatment regimen at the outset, curing more HER2+ BC patients and improving their quality of life. John Wiley and Sons Inc. 2023-05-31 /pmc/articles/PMC10432420/ /pubmed/37254964 http://dx.doi.org/10.1002/cnr2.1841 Text en © 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews He, Xuexin Yeung, Sai‐Ching J. Esteva, Francisco J. A new paradigm for classifying and treating HER2‐positive breast cancer |
title | A new paradigm for classifying and treating HER2‐positive breast cancer |
title_full | A new paradigm for classifying and treating HER2‐positive breast cancer |
title_fullStr | A new paradigm for classifying and treating HER2‐positive breast cancer |
title_full_unstemmed | A new paradigm for classifying and treating HER2‐positive breast cancer |
title_short | A new paradigm for classifying and treating HER2‐positive breast cancer |
title_sort | new paradigm for classifying and treating her2‐positive breast cancer |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432420/ https://www.ncbi.nlm.nih.gov/pubmed/37254964 http://dx.doi.org/10.1002/cnr2.1841 |
work_keys_str_mv | AT hexuexin anewparadigmforclassifyingandtreatingher2positivebreastcancer AT yeungsaichingj anewparadigmforclassifyingandtreatingher2positivebreastcancer AT estevafranciscoj anewparadigmforclassifyingandtreatingher2positivebreastcancer AT hexuexin newparadigmforclassifyingandtreatingher2positivebreastcancer AT yeungsaichingj newparadigmforclassifyingandtreatingher2positivebreastcancer AT estevafranciscoj newparadigmforclassifyingandtreatingher2positivebreastcancer |